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Abstract
Background: Use of statins has been suggested to protect against renal cell carcinoma
(RCC); however, studies have typically been underpowered, and the results are con-
flicting.
Objective: To determine whether the use of statins is associated with a reduced risk of
RCC using high-quality registry data.
Design, setting, and participants: We conducted a nationwide case–control study based
on all histologically veriﬁed cases of RCC in Denmark between 2002 and 2012 (n = 4606)
matched 1:10 to cancer-free controls. Data on drug use, comorbidity, and educational
level were obtained from Danish nationwide prescription, patient, and demographic
registries.
Outcome measurements and statistical analysis: Odds ratios (ORs) and 95% conﬁdence
intervals (CIs) for RCC associated with long-term use (5 yr) of statins were estimated
using conditional logistic regression, adjusting for potential confounders.
Results and limitations: The adjusted OR for RCC associated with long-term use of
statins was 1.06 (95% CI, 0.91–1.23). Analyses stratiﬁed by duration of statin use, type of
statin, and patient characteristics all yielded ORs close to unity, except for a slightly
increased OR for RCC associatedwith long-term statin use amongwomen (OR: 1.25; 95%
CI, 0.96–1.62). The main limitation of our study was lack of information on lifestyle
factors, notably obesity, which may have biased the risk estimates upward.
Conclusions: Our study does not support an important chemopreventive effect of long-
term statin use against RCC. The marginally increased and statistically insigniﬁcant risk
estimates can readily be interpreted as a null ﬁnding, considering the lack of control for
obesity and other lifestyle risk factors.
Patient summary: Previous studies have shown that the use of cholesterol-lowering
drugs (statins) may protect against renal cancer. In a large study including all Danish
renal cancers during an 11-yr period, we found no evidence of such an effect.
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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1. Introduction
Although laboratory studies have consistently demonstrat-
ed the antineoplastic effects of statins against several cancer
types [1–3], epidemiological studies are conflicting regard-
ing the association between statin use and cancer risk
[3–6]. Studies that have reported results for the association
between statin use and kidney cancer have also produced
equivocal results [7–13]. A cohort study of US veterans
reported a 48% reduction in the risk of renal cell carcinoma
(RCC) associated with statin use [10], and two small
population-based cohort studies found a similar inverse
association [11]. In contrast to these studies, other
epidemiological studies have found no apparent association
between statin use and the risk of RCC or kidney cancer
overall [7–9,12], and one study reported an increased risk of
kidney and other urologic cancers associatedwith statin use
[13].
The Danish health system offers unique opportunities to
study associations between drug use and cancer risk in large
population-based cohorts. Using a nationwide population-
based case–control design, we aimed to evaluate the
hypothesis that statin use is associated with a reduced
RCC risk.
2. Material and methods
The study was conducted as a nationwide case–control study. We
compared the use of statins among individuals diagnosed with RCC
(cases) with use among cancer-free individuals (controls) to estimate the
odds ratio (OR) for RCC associated with long-term use of statins deﬁned
as cumulative exposure of a minimum of 5 yr.
2.1. Data sources
We used data from ﬁve Danish nationwide registries: the Danish Cancer
Registry [14], the National Prescription Registry [15], the National
Patient Register [16], registers in Statistics Denmarkwith information on
level of education [17], and the Civil Registration System [18]. Supple-
ment 1 describes the data sources in detail.
Virtually all medical care in Denmark is furnished by the national
health authorities, allowing true population-based register-linkage
studies covering all inhabitants of Denmark. Data were linked by use
of the personal identiﬁcation number, a unique identiﬁer assigned to all
Danish residents since 1968 [18]. All linkages were performed within
Statistics Denmark, a governmental institution that collects and
processes information for a variety of statistical and scientiﬁc purposes.
2.2. Cases and controls
From the Danish Cancer Registry, we identiﬁed all individuals
in Denmark with a ﬁrst-time diagnosis of invasive parenchymal RCC
(ie, disregarding cancers of the pelvis and in situ cancers) between
January 1, 2002, and December 31, 2012. The date of cancer diagnosis
was deﬁned as the index date. To ensure the validity of our case
material, we restricted cases to histologically veriﬁed cases. Exclusion
criteria were age outside the range of 18–85 yr at the index date and
residency outside Denmark within 10 yr prior to the index date, thus
ensuring at least 10 yr of follow-up for all study subjects and aminimum
of 7 yr of prescription coverage (see Supplement 1). We further excluded
individuals with a history of cancer (except nonmelanoma skin cancer)
or conditions disposing to RCC including von Hippel-Lindau syndrome
(InternationalClassiﬁcationofDiseases [ICD]-8:75982; ICD-10:Q85.8–9),
cystic kidney disease (ICD-8: 59324; ICD-10: Q61), and tuberous sclerosis
(ICD-8: 31032, 31132, 31232, 31332, 31432, 31532, 75969; ICD-10:
Q851).
Controls were selected using risk set sampling. For each case, we
selected 10 controls among all Danish residents of the same gender and
birth year and applied the same selection criteria as for cases. Controls
were assigned an index date identical to that of the corresponding case.
Subjects were eligible for sampling as controls before they became
cases. The calculated ORs are unbiased estimates of the incidence rate
ratios that would have emerged from a cohort study in the source
population [19].
2.3. Exposure definition
Our primary exposure was the use of statins. ‘‘Ever use’’ of statins was
deﬁned as having ﬁlled two or more prescriptions (Anatomical
Therapeutic Chemical [ATC] code C10AA) of any statin prior to the
index date. Long-term use of statins was deﬁned as 5 yr of cumulative
use prior to the index date. We performed extensive sensitivity analyses
of the exposure deﬁnition. The duration of each prescription, required for
the estimation of cumulative exposure duration, is not recorded in the
National Prescription Registry. To overcome this limitation, we assumed
a daily intake of one tablet while adding 25% additional days to the
duration to allow for minor noncompliance and irregular reﬁll patterns.
In all exposure calculations, we disregarded prescriptions redeemed
within 1 yr prior to the index date. This was done to reduce the
possibility of reverse causation [20,21] and from the rationale that such
recent exposure is unlikely to be associated with cancer development.
2.4. Main analysis
The analysis followed a conventional matched case–control approach. In
the main analysis, we estimated ORs for RCC associated with long-term
use of statins. In all analyses, use of statins was compared with nonuse
(fewer than two prescriptions) of statins using conditional logistic
regression.
Using data from the prescription, patient, and demographic
registries, and disregarding the period 1 yr prior to the index date, we
incorporated a number of potential confounders in the analyses: (1) use
of drugs known or suspected to modify renal function or risk of RCC
including low-dose aspirin and nonaspirin nonsteroidal anti-inﬂamma-
tory drugs, paracetamol, thiazides, b-blockers, vascular calcium channel
blockers, inhibitors of the renin-angiotensin system, and loop diuretics;
(2) prior diagnoses of diseases known or suspected to modify renal
function or risk of renal or other cancers including hypertension, type
1 or type 2 diabetes, chronic obstructive pulmonary disease, alcohol-
related disease, and moderate to severe renal disease; and (3) highest
achieved education (as a crude measure of socioeconomic status).
Supplementary Table 1 presents the details of the potential confounders
including codes.
2.5. Sensitivity and supplementary analyses
We performed a number of predeﬁned subanalyses and sensitivity
analyses. First, as an explorative analysis of a potential dose–response
effect, we performed analyses stratiﬁed according to cumulative use of
statins. This was done for statins overall and separately for hydrophilic,
lipophilic, and individual statin drugs (see Supplement 2 for deﬁnitions).
Second, we examined associations for RCC with statin use within
subgroups deﬁned by gender, age, or histories of renal disease, diabetes,
or hypertension. Third, we stratiﬁed the analyses by clinical stage,
deﬁned as localized or nonlocalized disease. Fourth, we changed the 1-yr
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lag time to zero or 2 yr, respectively. Finally, we used the ‘‘rule-out’’
approach, described by Schneeweiss [22], to assess the extent to which
any positive associations might be explained by unmeasured confound-
ing by overweight.
2.6. Other
All analyses were performed using Stata v.13.0 (StataCorp, College
Station, TX, USA). The study was approved by the Danish Data Protection
Agency. According to Danish law, studies based solely on register data do
not require approval from an ethics review board [23].
3. Results
We identified 5631 incident RCCs between January
2002 and December 2012. After exclusions, the study
population consisted of 4606 cancer cases (Fig. 1) whowere
matched to 46 060 controls.
Among cases, 24.0% were ever-users of statins and 6.7%
were long-term users (Table 1). The corresponding pre-
valences among controls were 19.1% and 4.9%, respectively.
This yielded an age- and gender-adjusted OR for RCC
associated with ever use of statins of 1.38 (95% confidence
interval [CI], 1.28–1.49) and for long-term use of 1.48 (95%
CI, 1.29–1.69). However, after adjustment for potential
confounders, the ORs declined to 1.06 (95% CI, 0.97–1.16)
for ever use and 1.06 (95% CI, 0.91–1.23) for long-term use
(Table 2).
The pronounced effect of the confounder adjustment is
further illustrated in Supplementary Table 2. All the
included potential confounders contributed to attenuation
of the association between statin use and RCC risk, notably
diagnoses of hypertension and inhibitors of the renin-
angiotensin system.
In analyses stratified by duration of statin use, all ORs
were close to unity (Table 2). Stratification by lipophilic or
hydrophilic statins (Supplementary Table 3) and by
individual statin drugs (Supplementary Table 4) did not
alter the associations materially. Analyses within prede-
fined subgroups of gender, age, comorbidity, or clinical
stage revealed a slightly but statistically nonsignificant
increased OR for RCC with long-term statin use among
women (OR: 1.25; 95% CI, 0.96–1.62), whereas no risk
variation was found according to the other subgroups
(Table 3).
In the sensitivity analysis including statin exposure
within 1 yr prior to the index date, the ORs increased
slightly. Overall, the adjusted OR for long-term statin use
increased to 1.14 (95% CI, 0.99–1.31), driven by an OR
for the last year preceding the index date of 1.22 (95% CI,
1.07–1.40). Increasing the lag period to 2 yr did not
influence the estimates.
We also ascertained whether the point estimate of
1.25 among women could be explained by residual
confounding from being overweight. The input for this
analysis was an estimated prevalence of overweight of
36.8% amongwomen [24] and an exposure prevalence of 4%
[(Fig._1)TD$FIG]
Fig. 1 – Flowchart of the selection of cases.
* Von Hippel-Lindau syndrome, cystic kidney disease, and tuberous
sclerosis.
Table 1 – Characteristics of renal cell carcinoma cases and their
matched controls
All cases
(n = 4606)
All controls
(n = 46 060)
Age, median, yr (IQR) 64 (57–72) 64 (57–72)
Male sex (%) 3052 (66.3) 30 520 (66.3)
Use of statins prior to index date (%)
Nonuse 3501 (76.0) 37 241 (80.9)
Ever use 1105 (24.0) 8819 (19.1)
Long-term use (5 yr) 307 (6.7) 2275 (4.9)
Drugs (%)
Nonaspirin NSAID 2661 (57.8) 23 737 (51.5)
Aspirin 1205 (26.2) 9638 (20.9)
Paracetamol 892 (19.4) 7128 (15.5)
Loop diuretics 619 (13.4) 4194 (9.1)
Thiazides 1212 (26.3) 8808 (19.1)
b-Blockers 1216 (26.4) 9086 (19.7)
Vascular calcium channel blockers 1075 (23.3) 7083 (15.4)
Inhibitors of RAS 1641 (35.6) 11 162 (24.2)
Medical history (%)
Hypertension 809 (17.6) 5212 (11.3)
Diabetes type 1 131 (2.8) 843 (1.8)
Diabetes type 2 503 (10.9) 3536 (7.7)
COPD 341 (7.4) 3015 (6.5)
Alcohol-related disease 364 (7.9) 3276 (7.1)
Moderate/severe renal disease 116 (2.5) 456 (1.0)
Highest achieved education, yr (%)
Short (7–10) 1811 (39.3) 16 820 (36.5)
Medium (11–13) 1808 (39.3) 17 975 (39.0)
Long (>13) 758 (16.5) 9336 (20.3)
COPD = chronic obstructive pulmonary disease; IQR = interquartile range;
NSAID = nonsteroidal anti-inﬂammatory drug; RAS = renin-angiotensin
system.
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among female controls (Table 3). A similar analysis was
performed, assuming the same exposure prevalence and a
smoker prevalence of 30.6% for women [25]. Both analyses
(Supplementary Fig. 1) showed that with ORs <2.0 for the
association between being overweight/smoking and RCC
risk, there would have to be an extremely strong association
between overweight/smoking and statin use to fully
account for an apparent OR of 1.25 if the true valuewas 1.00.
Finally, we performed a number of post hoc analyses. To
further evaluate the observed risk variation by gender, we
stratified the analyses of duration of statin use by gender
(Supplementary Table 5). In addition, we repeated the
analysis for women excluding users of any hormone
supplement prior to the index date, whereby the OR
increased from 1.25 to 1.42 (95% CI, 0.93–2.16). To further
investigate the influence of timing of statin use on RCC risk,
we restricted the study population to subjects with at least
10 yr of exposure data (ie, with index dates between
2005 and 2012; 77% of cases; n = 3526) and disregarded
exposure within the last 5 yr prior to the index date. The
overall OR of this analysis (1.03; 95% CI, 0.82–1.31) was
close to that of the main analysis (1.06). Lastly, to evaluate
the performance of our algorithm for cumulative exposure
of statins, we omitted the 25% added to the expected
duration of prescriptions for statins (see sect. 2). This
analysis also returned results similar to those of the main
analysis (data not shown).
4. Discussion
In this nationwide study including all Danish RCC cases
from 2002 to 2012, we found no evidence of a chemo-
preventive effect of long-term statin use on RCC. Except for
a slightly elevated OR for RCC among female statin users,
the risk estimates were all close to unity, and the results
were robust within a supplementary analysis of subgroups
and in dose–response analyses.
Our results are consistent with most of the studies of
statin use and risk of kidney cancer [7–9,12,26]. Three
studies reported a substantial reduction in risk of RCC or
kidney cancer overall with statin use [4,10,11]; however,
these results were prone to methodological shortcomings.
Table 3 – Associations between long-term exposure to statins (I5 yr) and risk of renal cell carcinoma, specified by patient subgroups or
cancer stage
Subgroup Cases, exposed/
unexposed, n/n
Controls, exposed/
unexposed, n/n
Adjusted ORa Adjusted ORb
All 307/3501 2275/37 241 1.48 (1.29–1.69) 1.06 (0.91–1.23)
Male 200/2312 1602/24 530 1.32 (1.12–1.56) 0.96 (0.80–1.16)
Female 107/1189 673/12 711 1.88 (1.49–2.37) 1.25 (0.96–1.62)
Age <50 yr –/461 17/4751 – –
Age 50–69 yr 143/2004 1018/21 593 1.55 (1.28–1.88) 0.99 (0.79–1.23)
Age 70 yr 161/1036 1240/10 897 1.40 (1.16–1.70) 1.13 (0.91–1.40)
No history of renal disease 289/3431 2212/36 978 1.46 (1.27–1.67) 1.08 (0.93–1.26)
No history of hypertension 162/3110 1432/34 732 1.32 (1.10–1.57) 1.06 (0.87–1.28)
No history of diabetes 207/3268 1734/35 291 1.33 (1.13–1.56) 0.92 (0.77–1.10)
Stage
Localised 195/2027 1361/21 966 1.61 (1.36–1.91) 1.05 (0.86–1.27)
Nonlocalised 64/1108 583/11 345 1.12 (0.85–1.48) 0.98 (0.72–1.34)
Unknown 48/366 331/3930 1.68 (1.19–2.37) 1.22 (0.82–1.83)
OR = odds ratio.
a Adjusted for age and sex (by design).
b Adjusted for (a) use of low-dose aspirin and nonaspirin nonsteroidal anti-inﬂammatory drugs, paracetamol, thiazides, b-blockers, vascular calcium channel
blockers, inhibitors of the renin-angiotensin system, and loop diuretics; (b) prior diagnoses of hypertension, type 1 or type 2 diabetes, chronic obstructive
pulmonary disease, alcohol-related disease, and moderate to severe renal disease; and (c) highest achieved education.
Table 2 – Association between exposure to statins and risk of renal cell carcinoma, specified by exposure pattern
Exposure group Cases, n Controls, n Adjusted ORa Adjusted ORb
Nonuse 3501 37 241 1.00 (ref.) 1.00 (ref.)
Ever use 1105 8819 1.38 (1.28–1.49) 1.06 (0.97–1.16)
Long-term use (5 yr) 307 2275 1.48 (1.29–1.69) 1.06 (0.91–1.23)
Cumulative duration of use
<1 yr 238 2128 1.20 (1.04–1.38) 1.00 (0.86–1.15)
1–4.99 yr 560 4416 1.42 (1.29–1.57) 1.09 (0.97–1.22)
5–9.99 yr 250 1879 1.46 (1.26–1.68) 1.03 (0.88–1.21)
10 yr 57 396 1.55 (1.15–2.08) 1.11 (0.81–1.51)
OR = odds ratio.
a Adjusted for age and sex (by design; risk-set matching).
b Adjusted for (a) use of low-dose aspirin and nonaspirin nonsteroidal anti-inﬂammatory drugs, paracetamol, thiazides, b-blockers, vascular calcium channel
blockers, inhibitors of the renin-angiotensin system, and loop diuretics; (b) prior diagnoses of hypertension, type 1 or type 2 diabetes, chronic obstructive
pulmonary disease, alcohol-related disease, and moderate to severe renal disease; and (c) highest achieved education.
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In the case–control study of US veterans by Khurana et al
[10], controls were drawn from among frequent users of the
Veterans Affairs system who may have been more likely to
be prescribed statins than the kidney cancer cases included
in the study, thus introducing selection bias. In the cohort
study by Liu et al [11], the inverse association between
statin use and RCC risk was confined to a subgroup of the
study population (ie, women without hypertension), and,
finally, the statistical precision and drug exposure period
were limited in the case–control study by Graaf et al [4]
preventing analyses according to duration of statin use for
cancer subsites. A 2014 meta-analysis, including data from
both observational studies and randomized trials, reported
a pooled risk ratio for the association between statin use
and kidney cancer close to unity (0.92; 95% CI, 0.71–1.19),
with no risk variation according to duration of statin use
[26].
The main limitation of our study is lack of individual
anthropometric data. Confounding from being overweight
would increase the observed OR. Because we could not test
directly the association between being overweight and RCC
risk, we used a sensitivity analysis based on published
reports of obesity and RCC risk to determine how large an
association between being overweight and statin use
would have to exist to account for the 1.25 OR point
estimate observed among women (Supplementary Fig. 1).
Our analyses showed that it is highly unlikely that theOR of
1.25 was entirely explained by residual confounding by
obesity or smoking, if the true ORwas 1.00. If we assume an
OR between being overweight and RCC of 1.34 for women,
as reported in one meta-analysis [27] and a risk ratio
between smoking and RCC of up to 1.58 reported in another
meta-analysis [28], then it becomes virtually impossible
that obesity and smoking are the sole explanations because
this would require that statins were almost exclusively
prescribed to obese or smoking patients. To our knowledge,
smoking and obesity have never been included in Danish
guidelines as indications for prescribing statins, except if
these risk factors were believed to have caused diabetes or
an atherosclerotic event. Both of these conditions were
well captured in our analysis. However, the CI of our
estimate included the null value, and thus we cannot rule
out that our finding is attributable to random error.
Importantly, in our analysis, confounding from lifestyle
factors appeared less important for the association
between statin use and risk of RCC than factors such as
hypertension and use of inhibitors of the renin-angiotensin
system (Supplementary Table 2).
Another limitation of our study was that we were not
able to categorize the RCC cases into histologic subgroups
(eg, clear cell carcinomas vs non–clear cell carcinomas).
Therefore, we cannot entirely exclude an association
between statin use and rare subtypes of RCC. Lastly, the
homogeneous, primarily white, Danish population may not
be representative of all users of statins.
The main strengths of our study were the large sample
size and the nationwide approach. In Denmark, we are
uniquely positioned to perform a population-based study
with almost complete population coverage because almost
all health care service in the country is administered by the
public health system. The RCC cases were identified from
the Danish Cancer Registry, which has accurate and
virtually complete registration of incident cancer in
Denmark [14,29], and the additional restriction to histolog-
ically verified cases further enhanced the case validity. The
use of the Danish National Prescription Registry also
ensured complete and high-quality assessment of drug
use [15], with up to 18 yr of drug exposure history.
5. Conclusions
Our large population-based study, including high-quality
register data and adjusting for important confounders, did
not support an important chemopreventive effect of long-
term statin use against RCC. We interpret the marginally
increased and statistically insignificant ORs for RCC with
long-term statin use as a null finding considering the lack of
control for obesity and other lifestyle risk factors.
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